The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study
Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at o...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.967026/full |
| _version_ | 1828351179863621632 |
|---|---|
| author | Xiya Wei Xiya Wei Yiyu Xie Yiyu Xie Ruoyu Jiang Ruoyu Jiang Huiyu Li Huiyu Li Heqing Wu Heqing Wu Yuqi Zhang Yuqi Zhang Ling Li Ling Li Shiyuan Zhou Shiyuan Zhou Xiao Ma Xiao Ma Zaixiang Tang Jun He Jun He Depei Wu Depei Wu Xiaojin Wu Xiaojin Wu |
| author_facet | Xiya Wei Xiya Wei Yiyu Xie Yiyu Xie Ruoyu Jiang Ruoyu Jiang Huiyu Li Huiyu Li Heqing Wu Heqing Wu Yuqi Zhang Yuqi Zhang Ling Li Ling Li Shiyuan Zhou Shiyuan Zhou Xiao Ma Xiao Ma Zaixiang Tang Jun He Jun He Depei Wu Depei Wu Xiaojin Wu Xiaojin Wu |
| author_sort | Xiya Wei |
| collection | DOAJ |
| description | Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at our center between January 2018 and December 2020, and then followed until December 2021. Based on whether a dose of 375mg/m2 rituximab was used at least once within two weeks before transplantation, patients undergoing allo-HSCT were classified into two groups: rituximab (N=176) and non-rituximab (N=344) group. Amongst all the patients, the application of rituximab decreased EBV reactivation (P<0.01) and rituximab was an independent factor in the prevention of EBV reactivation by both univariate and multivariate analyses (HR 0.56, 95%CI 0.33-0.97, P=0.04). In AML patients, there were significant differences in the cumulative incidence of aGVHD between the two groups (P=0.04). Our data showed that rituximab was association with a decreased incidence of aGVHD in AML patients according to both univariate and multivariate analyses. There was no difference between the two groups in other sets of populations. Thus, our study indicated that rituximab administered before transplantation may help prevent EBV reactivation in all allo-HSCT patients, as well as prevent aGVHD in AML patients after allo-HSCT. |
| first_indexed | 2024-04-14T01:35:50Z |
| format | Article |
| id | doaj.art-7fb521fbebb541b596e47424cbe12e9d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-14T01:35:50Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7fb521fbebb541b596e47424cbe12e9d2022-12-22T02:19:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.967026967026The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world studyXiya Wei0Xiya Wei1Yiyu Xie2Yiyu Xie3Ruoyu Jiang4Ruoyu Jiang5Huiyu Li6Huiyu Li7Heqing Wu8Heqing Wu9Yuqi Zhang10Yuqi Zhang11Ling Li12Ling Li13Shiyuan Zhou14Shiyuan Zhou15Xiao Ma16Xiao Ma17Zaixiang Tang18Jun He19Jun He20Depei Wu21Depei Wu22Xiaojin Wu23Xiaojin Wu24National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Internal Medicine, Yale-New Haven Health/Bridgeport Hospital, Bridgeport, CT, United StatesNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaDepartment of Epidemiology and Statistics, School of Public Health, Faculty of Medicine, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, ChinaInstitute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaRituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at our center between January 2018 and December 2020, and then followed until December 2021. Based on whether a dose of 375mg/m2 rituximab was used at least once within two weeks before transplantation, patients undergoing allo-HSCT were classified into two groups: rituximab (N=176) and non-rituximab (N=344) group. Amongst all the patients, the application of rituximab decreased EBV reactivation (P<0.01) and rituximab was an independent factor in the prevention of EBV reactivation by both univariate and multivariate analyses (HR 0.56, 95%CI 0.33-0.97, P=0.04). In AML patients, there were significant differences in the cumulative incidence of aGVHD between the two groups (P=0.04). Our data showed that rituximab was association with a decreased incidence of aGVHD in AML patients according to both univariate and multivariate analyses. There was no difference between the two groups in other sets of populations. Thus, our study indicated that rituximab administered before transplantation may help prevent EBV reactivation in all allo-HSCT patients, as well as prevent aGVHD in AML patients after allo-HSCT.https://www.frontiersin.org/articles/10.3389/fimmu.2022.967026/fullrituximabB cellprior to transplantationallogeneic hematopoietic stem cell transplantationEBV - Epstein-Barr virusaGVHD: acute graft vs host disease |
| spellingShingle | Xiya Wei Xiya Wei Yiyu Xie Yiyu Xie Ruoyu Jiang Ruoyu Jiang Huiyu Li Huiyu Li Heqing Wu Heqing Wu Yuqi Zhang Yuqi Zhang Ling Li Ling Li Shiyuan Zhou Shiyuan Zhou Xiao Ma Xiao Ma Zaixiang Tang Jun He Jun He Depei Wu Depei Wu Xiaojin Wu Xiaojin Wu The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study Frontiers in Immunology rituximab B cell prior to transplantation allogeneic hematopoietic stem cell transplantation EBV - Epstein-Barr virus aGVHD: acute graft vs host disease |
| title | The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study |
| title_full | The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study |
| title_fullStr | The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study |
| title_full_unstemmed | The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study |
| title_short | The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study |
| title_sort | impact of rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation a real world study |
| topic | rituximab B cell prior to transplantation allogeneic hematopoietic stem cell transplantation EBV - Epstein-Barr virus aGVHD: acute graft vs host disease |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.967026/full |
| work_keys_str_mv | AT xiyawei theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiyawei theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yiyuxie theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yiyuxie theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT ruoyujiang theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT ruoyujiang theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT huiyuli theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT huiyuli theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT heqingwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT heqingwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yuqizhang theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yuqizhang theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT lingli theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT lingli theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT shiyuanzhou theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT shiyuanzhou theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaoma theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaoma theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT zaixiangtang theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT junhe theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT junhe theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT depeiwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT depeiwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaojinwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaojinwu theimpactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiyawei impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiyawei impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yiyuxie impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yiyuxie impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT ruoyujiang impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT ruoyujiang impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT huiyuli impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT huiyuli impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT heqingwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT heqingwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yuqizhang impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT yuqizhang impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT lingli impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT lingli impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT shiyuanzhou impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT shiyuanzhou impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaoma impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaoma impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT zaixiangtang impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT junhe impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT junhe impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT depeiwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT depeiwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaojinwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy AT xiaojinwu impactofrituximabadministeredbeforetransplantationinpatientsundergoingallogeneichematopoieticstemcelltransplantationarealworldstudy |